| Home  | About ScienceAsia  | Publication charge  | Advertise with us  | Subscription for printed version  | Contact us  
Editorial Board
Journal Policy
Instructions for Authors
Online submission
Author Login
Reviewer Login
Volume 45 Number 2
Volume 45 Number 1
Volume 44 Number 6
Volume 44 Number 5
Volume 44 Number 4
Volume 44 Number 3
Earlier issues
Volume 39 Number 3 Volume 39 Number 4 Volume 39 Number 5

previous article next article 1

Research articles

ScienceAsia 39(2013): 369-375 |doi: 10.2306/scienceasia1513-1874.2013.39.369


Interaction of rosiglitazone and pioglitazone with organic cation transporters


Sirima Soodvilaia, Chatchai Muanprasatb,c, Varanuj Chatsudthipongb,c, Sunhapas Soodvilaib,c,*

 
ABSTRACT:     Thiazolidinedione drugs (TZDs) are used in the treatment of type 2 diabetes mellitus (DM). This study aimed to investigate the potential influence of TZDs on organic cation transporters (OCTs). Such interactions were examined using Chinese hamster ovary (CHO-K1) cells stably and singly transfected with rabbit (rb)OCT1 and rbOCT2, and in cells that endogenously express OCT1 (HepG2 cells) and OCT2 (LLC-PK1 cells). Rosiglitazone but not pioglitazone inhibited OCT1- and OCT2-mediated 3H-MPP+ uptake with half maximal inhibitory concentration (IC50) of 7.4±1.2 µM and 2.5±0.4 µM, respectively. The mode of inhibition by rosiglitazone was further determined using kinetic analysis. We showed that rosiglitazone decreased the maximal transport (Vmax) without affecting the transporter affinity (Km), indicating that the inhibitory effect of rosiglitazone on OCT1 and OCT2 entails a noncompetitive mechanism. Similarly, the inhibitory effect of rosiglitazone on MPP+ uptake was observed in OCT1 and OCT2 endogenously expressed. We conclude that rosiglitazone may inhibit transport activity of OCT1 and OCT2 by interfering with a non-substrate-binding site on the transporters. Since rosiglitazone is used in combination with other drugs to treat DM-related diseases, its inhibitory effect on OCTs may influence the pharmacokinetic of cationic drugs.

Download PDF

4 Downloads 378 Views


a Department of Pharmaceutical Technology, Faculty of Pharmacy, Rangsit University, Pathumthani, Thailand
b Department of Physiology, Faculty of Science, Mahidol University, Bangkok, Thailand
c Research Centre of Transport Protein for Medical Innovation, Faculty of Science, Mahidol University, Bangkok, Thailand

* Corresponding author, E-mail: sunhapas.soo@mahidol.ac.th

Received 12 Nov 2012, Accepted 9 Apr 2013